Previous 10 | Next 10 |
2024-01-24 20:45:03 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed Q2 2024 Earnings Preview ResMed product recall classified as most serious by FDA (update) Read the full article on Seeking Al...
2024-01-24 16:10:05 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards ResMed Q2 2024 Earnings Preview ResMed product recall classified as most serious...
Year-over-year revenue grows 12% , operating profit down 2% , non-GAAP operating profit up 20% Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m....
FFW Corp. (FFWC) is expected to report for Q2 2024 ResMed Inc. (RMD) is expected to report $1.81 for Q2 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2023-12-31 ChoiceOne Financial Services Inc. (COFS) is expected to report $0.64 for Q4 2023 First ...
2024-01-23 17:35:36 ET Major earnings expected after the bell on Wednesday include: Tesla ( TSLA ) International Business Machines Corporation ( IBM ) ServiceNow ( NOW ) Lam Research Corporation ( LRCX ) Crown Castle ( CCI ) Read the full ar...
2024-01-23 17:35:15 ET More on ResMed Why ResMed Is One Of My Top Picks In 2024 ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards ResMed product recall classified as most serious by FDA (update) ResMed masks to...
2024-01-22 00:41:37 ET Summary I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will have little effect on the Company. ...
2024-01-18 15:04:14 ET More on ResMed ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards A First Look At ResMed ResMed masks to remain on market despite recall: report ResMed alerts customers to potential magnet...
2024-01-16 11:41:19 ET More on ResMed ResMed: Putting GLP-1 Myths To Sleep ResMed: A Buy For Investors Seeking Long-Term Rewards A First Look At ResMed ResMed alerts customers to potential magnetic interference from masks ResMed secures victory in pat...
2024-01-10 22:09:45 ET Summary ResMed, a leader in digital health with over 22.5 million cloud-connected devices sold, excels in treating respiratory disorders like sleep apnea, impacting over 1 billion globally. Recent data from ResMed challenges the misconception that GLP-1 obes...
News, Short Squeeze, Breakout and More Instantly...
Insulet Corporation (NASDAQ: PODD) reported GAAP earnings per share of 73 cents for first-quarter 2024, which significantly improved from the year-...
Inspire Medical Systems, Inc. (NYSE: INSP) delivered a loss per share of 34 cents in first-quarter 2024, narrower than the year-ago period's lo...
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, beginni...